Guardant Health (GH) Projected to Post Quarterly Earnings on Wednesday

Guardant Health (NASDAQ:GH - Get Free Report) is projected to announce its Q1 2025 earnings results after the market closes on Wednesday, April 30th. Analysts expect the company to announce earnings of ($0.57) per share and revenue of $189.91 million for the quarter. Guardant Health has set its FY 2025 guidance at EPS.

Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Thursday, February 20th. The company reported ($0.90) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.15). Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The company had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Price Performance

GH stock opened at $43.80 on Wednesday. Guardant Health has a 1 year low of $16.77 and a 1 year high of $50.89. The firm has a 50-day moving average of $43.43 and a 200 day moving average of $36.76. The company has a market cap of $5.41 billion, a P/E ratio of -12.30 and a beta of 1.45.

Analyst Upgrades and Downgrades

GH has been the subject of a number of research analyst reports. JPMorgan Chase & Co. raised their target price on Guardant Health from $50.00 to $55.00 and gave the company an "overweight" rating in a research note on Friday, February 21st. Piper Sandler boosted their target price on shares of Guardant Health from $34.00 to $50.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Morgan Stanley increased their price target on shares of Guardant Health from $42.00 to $52.00 and gave the stock an "overweight" rating in a research note on Thursday, March 6th. Barclays dropped their price objective on shares of Guardant Health from $60.00 to $55.00 and set an "overweight" rating on the stock in a research note on Thursday, April 10th. Finally, Guggenheim reaffirmed a "buy" rating and set a $56.00 target price on shares of Guardant Health in a research note on Monday, February 24th. Twenty investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Guardant Health has a consensus rating of "Buy" and an average target price of $49.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.